profit from every $100 of sales.
$0$100
Coeptis Therapeutics
We have no price for Coeptis Therapeutics since 24 April 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$16.40+1.17% today
+5.5% since Oct 13, 25
1-year low $10.401-year high $18.80
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Coeptis Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $1.36 million in 2025, with -$11.9 million of profit last year.
SalesProfit
Coeptis Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Coeptis Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Coeptis Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 1 | |
| 0 | 0 | 0 | 1 | |
| -34 | -21 | -10 | -13 | |
| -36 | -20 | -9 | -10 | |
| -38 | -21 | -11 | -12 | |
| -52.60 | -16.56 | -5.56 | – | |
| – | – | – | 86.7% | |
| – | – | – | -956.9% | |
| – | – | – | -874.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 8 | 5 | 9 | 16 |
| Cash | 4 | 1 | 1 | 6 |
| Total debt | 2 | 1 | 1 | 0 |
| Total liabilities | 3 | 4 | 5 | 2 |
| 4 | 1 | 3 | 14 | |
| 1 | 1 | 2 | – | |
| -453.3% | -820.1% | -172.1% | -66.5% | |
| -843.7% | -2,612.7% | -315.8% | -87.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -4 | -7 | -7 | -9 | |
| – | – | – | – | |
| -4 | -7 | -7 | -9 | |
| Dividends paid | – | – | – | – |
| 0 | – | – | – | |
| 0 | 0 | 1 | 1 |
Valuation
- –
- –
- –
- 5.8×
- 42.3×
- –
- –
- -14.9%
- -20.7%
- 0.0%
Profitability
- 86.7%
- -956.9%
- -874.3%
- -769.0%
- -71.4%
- -294.3%
- -89.6%
- -60.0%
- -71.8%
- 100.9%
Growth
- +106.5%
- –
- −29.4%
- –
- +42.7%
Financial health
- -0.5×
- 0.01
- 0.5%
- -22.4×
- 3.25
- 3.25
- 0.07
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 3%of 946
Top 5%of 867
Bottom 7%of 986
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -1.11 | – | – |
| Mar 19, 2026 | -0.12 | -0.80 | +85.0% |
| Nov 13, 2025 | -0.58 | – | – |
| Aug 14, 2025 | -1.17 | – | – |
| May 14, 2025 | -1.11 | – | – |
| Mar 28, 2025 | -1.01 | -0.80 | −26.5% |
| Nov 13, 2024 | -0.05 | -0.05 | +0.0% |
| Aug 16, 2024 | -0.08 | -0.09 | +11.1% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
36No pass
Benjamin Graham
42No pass
Philip Fisher
54No pass
Peter Lynch
0No pass
Joel Greenblatt
2No pass
Charlie Munger
53No pass
Terry Smith
47No pass
Questions about Coeptis Therapeutics
Is Coeptis Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Coeptis Therapeutics AI analysis
What does Coeptis Therapeutics do?
Coeptis Therapeutics, Inc. is a biopharmaceutical company dedicated to the advancement and market introduction of both generic and proprietary pharmaceutical products, as well as cell therapy platforms, specifically for individuals battling cancer. It is in Biotechnology.
Does Coeptis Therapeutics pay a dividend?
No. Coeptis Therapeutics does not pay a dividend at the moment.
Is Coeptis Therapeutics stock halal?
Yes. Coeptis Therapeutics passes our halal screen: its business is permitted and its debt is 0.5% of its market value, under the 30% limit. How we check
Who are Coeptis Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Coeptis Therapeutics's.
Prices: daily closes to Apr 24, 2026. Fundamentals: company reports via invest-like data.